MDM2 counteracts resistance to CDK4/6 inhibitors for melanoma therapy

A study from Vanderbilt-Ingram Cancer Center and the Department of Veterans Affairs led by Anna Vilgelm, MD, Ph.D., and Ann Richmond, Ph.D., has identified a possible second-line treatment for melanoma patients. The potential treatment would render CDK4/6 inhibitors, a class of drugs prescribed for some breast cancers, also effective against melanoma by combining the inhibitors with MDM2 compounds, which are […]

Continue reading »

Diet high in leucine may fuel breast cancer’s drug resistance

About one in eight women in the United States will develop breast cancer in their lifetime. The vast majority of these cancers rely on the hormone estrogen to grow. Estrogen-receptor positive (ER+) breast cancer tumors are frequently treated with the drug tamoxifen, which blocks the hormone’s effect on the tumor. However, many tumors eventually become resistant to tamoxifen, allowing cancer […]

Continue reading »

Flu virus could evolve resistance to pandemic drug: study

The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found. Scientists at Imperial College London, in collaboration with Public Health England, have discovered that two genetic mutations would be needed for the virus to develop resistance to favipiravir, an experimental antiviral […]

Continue reading »

Computer algorithm maps cancer resistance to drugs, therapy

New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center. The scientists wanted to examine how cancers acquire resistance to treatment over time and whether those changes could be modeled computationally to determine patient-specific timelines of resistance. The research was published by Genome Medicine […]

Continue reading »

New treatment to reverse drug resistance in some cancers

University of Queensland researchers have discovered how to reverse drug resistance in skin and mouth squamous cell carcinomas. UQ Diamantina Institute Associate Professor Nicholas Saunders said squamous cell carcinomas was curable when diagnosed early but difficult to eradicate once the cancer spread. “This cancer of the skin and mouth kills approximately 1,400 Australians each year,” Dr. Saunders said. “The drugs […]

Continue reading »

Abdominal fat secretes novel adipokine promoting insulin resistance and inflammation

An international research team in which the DZD is participating has identified a novel adipokine that favors the development of insulin resistance and systemic inflammation. In cases of severe obesity, this adipokine is secreted by the adipocytes of the abdominal fat tissue and released into the bloodstream. The new findings could contribute to the development of alternative approaches for the […]

Continue reading »

Mixed progress on drug resistance in A. baumannii infections in children

In the first national study of the prevalence of antibiotic-resistant Acinetobacter baumannii infections in children across the US, researchers from Center for Disease Dynamics, Economics, & Policy (CDDEP) in Washington, DC and Rush University in Chicago, IL examined national and regional trends of antibiotic resistance in clinical specimens over a 13-year period. While there was an overall increase between 1999 […]

Continue reading »

Researchers describe role of novel mutations in fosfomycin resistance

Researchers identified novel chromosomal mutations and described their role in the development of resistance of Escherichia coli (E. coli) to broad-spectrum antibiotic fosfomycin, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Researchers from France studied the genetic basis of fosfomycin resistance in a panel of E. coli isolates and found that certain […]

Continue reading »

New paper suggests that tumor cells may develop resistance to potential Ras inhibitors

Researchers have long sought a treatment aimed specifically at the Ras family of genes, the most common oncogenes and those that initiate many of the most lethal tumours. However, the results of a hypothetical treatment may be far less positive than speculated, according to a manuscript published in Genes & Development by the Genomic Instability Group at the Spanish National […]

Continue reading »